Stay updated on ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial
Sign up to get notified when there's something new on the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page.

Latest updates to the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include new drug information related to cancer treatment, specifically mentioning Fluorouracil and Irinotecan, along with a new revision number. However, significant details about a previous study comparing ABT-165 and bevacizumab have been removed.SummaryDifference9%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page.